Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy
We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 da...
Gespeichert in:
Veröffentlicht in: | Clinical infectious diseases 1999-01, Vol.28 (Supplement-1), p.S57-S65 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S65 |
---|---|
container_issue | Supplement-1 |
container_start_page | S57 |
container_title | Clinical infectious diseases |
container_volume | 28 |
creator | Joesoef, M. R. Schmid, G. P. Hillier, S. L. |
description | We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic diseases, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners. |
doi_str_mv | 10.1086/514725 |
format | Article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_69593846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4460675</jstor_id><sourcerecordid>4460675</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-d028f6baf23bf35532bd791514a0a964ec4ec3a69d96f85712941b28b8a03c573</originalsourceid><addsrcrecordid>eNpNkFtPJCEQhYlZo66XX2BMP5h9a4WmoWHfdLLrJSbeRrPZF1LdDYr2NCMwXv69jD1RE5Kq1Pk4BQehLYL3CBZ8n5GyKtgSWiOMVjlnkvxIPWYiLwUVq-hnCA8YEyIwW0GrBONCEILXkDqEJmpvoctu4c72LtjwO7vSz1a_ZM5kY68hTnQfs_NptK4PGfRtduFiGs0vjTrb2yY1J32b6oAY57PxvfYwfdtAywa6oDcXdR3d_P0zHh3nZ-dHJ6ODs7yhksW8Te8xvAZT0NpQxmhRt5Uk6VeAQfJSN-lQ4LKV3AhWkUKWpC5ELQDThlV0Hf0afKfePc10iGpiQ6O7DnrtZkFxySQVJf8CG-9C8NqoqbcT8G-KYDWPUg1RJnBn4TirJ7r9hg3ZJWB3AUBICRgPfWPDF8cFwx_Y9oA9hOj8p1yWHPNqviYfZBuifv2UwT8qXtGKqeN__xU5wsXh9fhSndJ3SziSSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69593846</pqid></control><display><type>article</type><title>Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Joesoef, M. R. ; Schmid, G. P. ; Hillier, S. L.</creator><creatorcontrib>Joesoef, M. R. ; Schmid, G. P. ; Hillier, S. L.</creatorcontrib><description>We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic diseases, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/514725</identifier><identifier>PMID: 10028110</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Bacterial diseases ; Bacterial diseases of the genital system ; Bacterial vaginosis ; Biological and medical sciences ; Cream ; Dosage ; Experimentation ; Female ; Gels ; Human bacterial diseases ; Humans ; Infections ; Infectious diseases ; Male ; Medical sciences ; Placebos ; Pregnancy ; Pregnancy outcome ; Sexually transmitted diseases ; Vaginosis, Bacterial - drug therapy</subject><ispartof>Clinical infectious diseases, 1999-01, Vol.28 (Supplement-1), p.S57-S65</ispartof><rights>Copyright 1999 The Infectious Diseases Society of America</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-d028f6baf23bf35532bd791514a0a964ec4ec3a69d96f85712941b28b8a03c573</citedby><cites>FETCH-LOGICAL-c395t-d028f6baf23bf35532bd791514a0a964ec4ec3a69d96f85712941b28b8a03c573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4460675$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4460675$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,803,4047,4048,23928,23929,25138,27922,27923,58015,58248</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1685010$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10028110$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joesoef, M. R.</creatorcontrib><creatorcontrib>Schmid, G. P.</creatorcontrib><creatorcontrib>Hillier, S. L.</creatorcontrib><title>Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic diseases, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.</description><subject>Bacterial diseases</subject><subject>Bacterial diseases of the genital system</subject><subject>Bacterial vaginosis</subject><subject>Biological and medical sciences</subject><subject>Cream</subject><subject>Dosage</subject><subject>Experimentation</subject><subject>Female</subject><subject>Gels</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Placebos</subject><subject>Pregnancy</subject><subject>Pregnancy outcome</subject><subject>Sexually transmitted diseases</subject><subject>Vaginosis, Bacterial - drug therapy</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkFtPJCEQhYlZo66XX2BMP5h9a4WmoWHfdLLrJSbeRrPZF1LdDYr2NCMwXv69jD1RE5Kq1Pk4BQehLYL3CBZ8n5GyKtgSWiOMVjlnkvxIPWYiLwUVq-hnCA8YEyIwW0GrBONCEILXkDqEJmpvoctu4c72LtjwO7vSz1a_ZM5kY68hTnQfs_NptK4PGfRtduFiGs0vjTrb2yY1J32b6oAY57PxvfYwfdtAywa6oDcXdR3d_P0zHh3nZ-dHJ6ODs7yhksW8Te8xvAZT0NpQxmhRt5Uk6VeAQfJSN-lQ4LKV3AhWkUKWpC5ELQDThlV0Hf0afKfePc10iGpiQ6O7DnrtZkFxySQVJf8CG-9C8NqoqbcT8G-KYDWPUg1RJnBn4TirJ7r9hg3ZJWB3AUBICRgPfWPDF8cFwx_Y9oA9hOj8p1yWHPNqviYfZBuifv2UwT8qXtGKqeN__xU5wsXh9fhSndJ3SziSSg</recordid><startdate>199901</startdate><enddate>199901</enddate><creator>Joesoef, M. R.</creator><creator>Schmid, G. P.</creator><creator>Hillier, S. L.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199901</creationdate><title>Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy</title><author>Joesoef, M. R. ; Schmid, G. P. ; Hillier, S. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-d028f6baf23bf35532bd791514a0a964ec4ec3a69d96f85712941b28b8a03c573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Bacterial diseases</topic><topic>Bacterial diseases of the genital system</topic><topic>Bacterial vaginosis</topic><topic>Biological and medical sciences</topic><topic>Cream</topic><topic>Dosage</topic><topic>Experimentation</topic><topic>Female</topic><topic>Gels</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Placebos</topic><topic>Pregnancy</topic><topic>Pregnancy outcome</topic><topic>Sexually transmitted diseases</topic><topic>Vaginosis, Bacterial - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joesoef, M. R.</creatorcontrib><creatorcontrib>Schmid, G. P.</creatorcontrib><creatorcontrib>Hillier, S. L.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joesoef, M. R.</au><au>Schmid, G. P.</au><au>Hillier, S. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>1999-01</date><risdate>1999</risdate><volume>28</volume><issue>Supplement-1</issue><spage>S57</spage><epage>S65</epage><pages>S57-S65</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic diseases, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>10028110</pmid><doi>10.1086/514725</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1058-4838 |
ispartof | Clinical infectious diseases, 1999-01, Vol.28 (Supplement-1), p.S57-S65 |
issn | 1058-4838 1537-6591 |
language | eng |
recordid | cdi_proquest_miscellaneous_69593846 |
source | MEDLINE; JSTOR Archive Collection A-Z Listing; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
subjects | Bacterial diseases Bacterial diseases of the genital system Bacterial vaginosis Biological and medical sciences Cream Dosage Experimentation Female Gels Human bacterial diseases Humans Infections Infectious diseases Male Medical sciences Placebos Pregnancy Pregnancy outcome Sexually transmitted diseases Vaginosis, Bacterial - drug therapy |
title | Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T05%3A19%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bacterial%20Vaginosis:%20Review%20of%20Treatment%20Options%20and%20Potential%20Clinical%20Indications%20for%20Therapy&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Joesoef,%20M.%20R.&rft.date=1999-01&rft.volume=28&rft.issue=Supplement-1&rft.spage=S57&rft.epage=S65&rft.pages=S57-S65&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/514725&rft_dat=%3Cjstor_proqu%3E4460675%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69593846&rft_id=info:pmid/10028110&rft_jstor_id=4460675&rfr_iscdi=true |